Related by context. All words. (Click for frequent words.) 65 PRTX 64 HspE7 64 Cethromycin 64 antiviral activity 64 HGS ETR1 63 potent antiviral 63 IDX# 63 INCB# [001] 63 ribavirin RBV 63 elagolix 63 Traficet EN 63 oral prodrug 62 favorable pharmacokinetic profile 62 PEG Interferon lambda 62 nitazoxanide 62 Reverset 62 NGX# 62 pomalidomide 62 GLYX 62 Valortim 62 Viramidine 62 vicriviroc 62 elotuzumab 62 radezolid 62 PEG SN# 62 antiviral efficacy 62 celgosivir 62 nucleotide analog 62 valopicitabine 62 SparVax TM 62 Amigal 61 Bevirimat 61 OncoVEX GM CSF 61 cannabinor 61 CCR5 antagonist 61 PRT# 61 CCX# 61 R#/MEM # 61 Gag polymorphisms 61 Sym# 61 XmAb# 61 TRIOLEX 61 ITMN 61 elvucitabine 61 GAMMAGARD 61 Telintra 61 velafermin 61 Phenoptin 61 maturation inhibitor 61 Altastaph 61 Triolex 61 CR# vcMMAE 61 polymerase inhibitor 61 Phase Ib study 61 RDEA# 61 phase IIb clinical 61 Bezielle 61 immunomodulator 61 OHR/AVR# 61 viral kinetics 60 APTIVUS r 60 IRX 2 60 nucleoside analogues 60 Aurexis 60 solithromycin 60 RGB # 60 Phase 2a trial 60 Symadex 60 pradefovir 60 virologic 60 Actilon 60 alagebrium 60 integrase inhibitor 60 pegylated interferon 60 AVN# [001] 60 peginterferon 60 ganetespib 60 bosutinib 60 TG# [003] 60 AEGR 60 delafloxacin 60 S/GSK# 60 antiviral potency 60 LY# [003] 60 ISIS # 60 HCV 60 IMGN# 60 HCV replicon 60 Plicera 60 HCV protease inhibitor 60 DermaVir Patch 60 non nucleoside HCV 60 VLP vaccine 60 H#N# VLP vaccine 60 administered subcutaneously 60 forodesine 60 otelixizumab 60 virologic failure 60 refractory gout 59 Alocrest 59 ALN VSP 59 protease inhibitor 59 Pimavanserin 59 nucleoside 59 Phase Ib clinical 59 oral bioavailability 59 Dasatinib 59 thrombopoietin 59 Phase 2b study 59 TBC# 59 Locteron 59 adefovir 59 urocortin 2 59 transcriptase inhibitor NNRTI 59 Phase 1b clinical 59 Omacetaxine 59 decitabine 59 PS# [001] 59 JAK inhibitor 59 PEG PAL 59 NNRTI 59 Pegasys ® 59 TMC# [001] 59 HCV protease 59 Thiovir 59 huC# DM4 59 pegylated interferon alpha 59 Aptivus ® 59 CoFactor 59 HuMax CD4 59 elvitegravir 59 lesinurad 59 LymphoStat B 59 Multimeric 59 caspofungin 59 CRx 59 LY# [002] 59 Panacos 59 NNRTIs 59 nanoviricide 59 glufosfamide 59 Archexin 59 eltrombopag 59 teriflunomide 59 iSONEP 59 telaprevir VX 59 subcutaneously administered 59 SCH # 59 HGS ETR2 59 bicifadine 59 Bicifadine 59 Valortim ® 58 NXL# 58 T#I [002] 58 PRX # 58 GLP toxicology studies 58 liposomal formulation 58 picoplatin 58 mapatumumab 58 maximally tolerated dose 58 GFT# 58 inecalcitol 58 tolevamer 58 NRTI 58 ALKS 58 preclinically 58 synthetic retinoid 58 IMA# 58 evaluating tivozanib 58 CBLC# 58 ANAVEX #-# [003] 58 Nasulin 58 CANCIDAS 58 ZYBRESTAT 58 SAR# [004] 58 CIMZIA TM 58 TOLAMBA 58 virus HCV protease inhibitor 58 phase IIa clinical 58 enfuvirtide 58 metaglidasen 58 ISENTRESS 58 Cytolin ® 58 ALN RSV# 58 lomitapide 58 IFN alpha 58 alvespimycin 58 Phase 2a clinical trials 58 orally bioavailable 58 torezolid 58 rilpivirine 58 Menerba 58 #ME# 58 T#I mutation 58 dimebon 58 raltegravir 58 GALNS 58 tezampanel 58 JVRS 58 Bavituximab 58 OncoVEX 58 obatoclax 58 rFIXFc 58 BAL# [001] 58 Azedra 58 CYC# 58 pharmacodynamic 58 Androxal TM 58 HCV genotype 1 58 HuMax CD# 58 Tyrima 58 custirsen 58 Phase 1b trial 58 Tamibarotene 58 Pegasys plus Copegus 58 itraconazole 58 nalbuphine ER 58 MYDICAR ® 58 imatinib therapy 58 ocrelizumab 58 intranasal formulation 58 PDE4 inhibitor 58 ANA# 58 AP# [003] 58 HCV RESPOND 2 58 plus ribavirin 58 pegylated 58 dasatinib 58 Onconase 58 Hsp# inhibitors 58 OXi# 58 MET amplification 58 ponatinib 58 denufosol 58 EVIZON 58 nanoviricide drug 58 cilengitide 58 Phase IIa clinical 58 maraviroc 58 interferon alpha 58 sustained virologic response 58 HCV polymerase inhibitor 58 CTAP# Capsules 58 CORT # 58 pegylated interferon alfa 2a 58 samalizumab 58 YONDELIS 58 mg RDEA# 58 CCR5 inhibitor 58 GSK# [001] 58 adipiplon 58 Ophena TM 58 Phase Ib 57 HCV infected 57 posaconazole 57 HCV polymerase inhibitors 57 Interferon alpha 57 ACTEMRA TM 57 diabetic neuropathic pain 57 antisense drug 57 ZOLINZA 57 GAP #B# 57 MAP# 57 PXD# 57 ImmunoVEX HSV2 57 GSK# [002] 57 Zolinza 57 Chemophase 57 NS#/#A protease 57 pan HDAC inhibitor 57 amrubicin 57 phase IIa 57 Phase 1a clinical 57 interferon alfa 57 cethromycin 57 highly immunogenic 57 apremilast 57 MAXY alpha 57 Vilazodone 57 zileuton 57 oral ridaforolimus 57 ELND# 57 ENMD # 57 ALTU 57 Genz # 57 dose limiting toxicities 57 BMS # 57 dose cohort 57 influenza VLP vaccine 57 bortezomib 57 Hepatitis C virus HCV 57 APTIVUS 57 Omacetaxine mepesuccinate 57 BAY #-# 57 Aurora kinase 57 Albuferon 57 RSD# 57 ARIKACE 57 mcg dose 57 Oral NKTR 57 Marqibo 57 proteasome inhibitor 57 chronic HCV infection 57 Phase IIa trial 57 Serdaxin 57 amphotericin B 57 ritonavir boosting 57 neutralizing antibody 57 riociguat 57 tolerability 57 telaprevir 57 dacetuzumab 57 BiTE 57 vilazodone 57 Ostarine 57 doripenem 57 Allovectin 7 R 57 PREZISTA r 57 pharmacokinetic profile 57 taxane 57 TransVax TM 57 CTCE 57 Phase #/#a 57 PSN# [002] 57 Tarvacin TM 57 oritavancin 57 MEK inhibitors 57 belinostat 57 nanomolar 57 INCB# [002] 57 TriRima 57 non nucleoside inhibitor 57 Synavive 57 initiate Phase 1b 57 protease inhibitor PI 57 AMN# [001] 57 antibody 57 Mipomersen 57 peginterferon alfa 2a 57 preclinical 57 telbivudine 57 Radezolid 57 torezolid phosphate 57 Dalbavancin 57 Elotuzumab 57 tolerability profile 57 K ras mutations 57 Gleevec resistant 57 Xanafide 57 APD# 57 nanoviricides 57 REP# 57 phase IIb 57 antiretroviral naive 57 serum antibody 57 insulin degludec 57 Tesetaxel 57 SRT# [003] 57 TACI Ig 57 rHuPH# 56 CEQ# 56 Zerenex 56 preclinical studies 56 Phase IIb trials 56 ARRY 56 ALN PCS 56 nilotinib 56 virus HCV infection 56 dose cohorts 56 polymerase inhibitors 56 ceftazidime 56 Corlux 56 INT# [002] 56 enzastaurin 56 Tarvacin 56 LEVADEX 56 humanized antibody 56 limiting toxicity 56 MAb 56 null responder 56 danoprevir 56 CCR9 antagonist 56 SinuNase 56 Phase Ia 56 castration resistant prostate cancer 56 chronic myeloid leukemia CML 56 Vacc 4x 56 axitinib 56 MDV# 56 ongoing Phase 1b 56 antiviral therapy 56 systemically administered 56 lumiliximab 56 EGFR TKI 56 investigational protease inhibitor 56 OMAPRO 56 EZN 56 AEG# 56 #I TM# 56 FluCide 56 Fodosine 56 Golimumab 56 DR Cysteamine 56 pharmacokinetics PK 56 VAPRISOL 56 INTELENCE 56 Aflibercept 56 teduglutide 56 DAVANAT R 56 IPL# 56 neutralizing antibodies 56 virological failure 56 MVA BN R 56 pegylated interferons 56 peg IFN 56 NP2 Enkephalin 56 Picoplatin 56 retapamulin 56 CRLX# 56 uric acid lowering 56 oral FTY# 56 ALN TTR 56 MGCD# [001] 56 anticancer therapies 56 tanespimycin 56 #mg dose [002] 56 tasimelteon 56 KNS # 56 VA# [002] 56 Arikace 56 BCR ABL inhibitors 56 Heplisav 56 subcutaneous PRO 56 Telaprevir 56 Hsp# inhibitor 56 seliciclib 56 vidofludimus 56 octreotide 56 relapsed MM 56 interferon IFN 56 HGS ETR1 mapatumumab 56 replicon 56 CYT# 56 alefacept 56 visilizumab 56 atacicept 56 JAK inhibitors 56 ALN TTR# 56 bevasiranib 56 selective modulator 56 LEXIVA r 56 Valortim R 56 ALVESCO 56 iniparib 56 Relivar 56 orally administered inhibitor 56 Phase 1b 56 Panzem R NCD 56 antiviral 56 viral suppression 56 Tezampanel 56 ORMD 56 μg dose 56 Seliciclib 56 Apoptone 56 NEUGENE 56 ABC/3TC 56 GLPG# 56 VQD 56 tecarfarin 56 Pradefovir 56 AEZS 56 pharmacodynamic profile 56 cancer immunotherapies 56 mRCC 56 pharmacodynamic properties 56 Nanobody 56 4CMenB 56 dosing cohorts 56 MAXY G# 56 GRNVAC1 56 ANAVEX #-# [002] 56 APOPTONE 56 pharmacodynamics 56 cangrelor 56 oral antiviral 56 etravirine 56 hour bronchodilation 56 TELINTRA 56 daptomycin 56 pharmacokinetic PK profile 56 UPLYSO 56 DXL# 56 Epivir 56 Phase #b/#a trial 56 ONTAK 56 Phase IIB 56 bendamustine 56 desvenlafaxine succinate 56 oral methylnaltrexone 56 Cannabinor 56 registrational 56 QLT# 56 PegIFN RBV 56 ceftaroline 56 seroprotection 56 dexpramipexole 56 active comparator 56 Elvitegravir 56 trodusquemine 55 NS4A 55 imatinib Gleevec ® 55 Oritavancin 55 Capesaris 55 mg kg dose 55 Cytolin R 55 PCK# 55 ocular formulation 55 thymalfasin 55 virologic responses 55 sapacitabine 55 immunogenic 55 immune modulatory 55 metastatic RCC 55 Asentar 55 tocilizumab 55 tipranavir 55 iclaprim 55 aclidinium 55 MyVax 55 TRV# [001] 55 epratuzumab 55 maribavir 55 CCR5 antagonists 55 HCD# [002] 55 tafamidis 55 MNTX 55 Lu AA# 55 anti leukemic 55 antibody fragment 55 cidofovir 55 NKTR 55 Epothilones 55 antibody MAb 55 Telbivudine 55 small molecule defensin 55 mGluR5 NAM 55 HuMax EGFr 55 Fx #A 55 rhThrombin 55 antisense 55 tenofovir disoproxil fumarate 55 bardoxolone methyl 55 Diamyd ® 55 Q#IR 55 REMUNE R 55 fidaxomicin 55 CXB# 55 Pralatrexate 55 DP b# 55 fostamatinib 55 PD LID 55 ATL# [001] 55 dosing cohort 55 paliperidone ER 55 ICA # 55 NVA# 55 eniluracil 55 inhibitor RG# 55 HCV protease inhibitors 55 Insegia 55 ribavirin therapy 55 omega interferon 55 pharmacokinetic PK study 55 humanized anti 55 sunitinib 55 cMET 55 hepatitis C virus 55 atovaquone 55 Alinia 55 RLY# 55 baminercept 55 Belerofon 55 SPRYCEL ® 55 lamivudine 55 tenofovir Viread 55 nonclinical studies 55 Amplimexon 55 Laquinimod 55 ascending doses 55 HGS# 55 Zalbin 55 Phase 2a 55 hematological cancers 55 NEUGENE antisense 55 mg dose 55 MYDICAR 55 entecavir 55 GRN#L 55 anti TNF 55 DPP4 55 CA4P 55 JAK1 55 HAART regimens 55 relapsed multiple myeloma 55 TDF FTC 55 abatacept 55 talabostat 55 pegloticase 55 investigational HCV polymerase 55 chlorambucil 55 live attenuated influenza 55 hepatitis C genotype 55 CINTREDEKIN BESUDOTOX 55 HQK 55 hemagglutination inhibition 55 ritonavir boosted 55 HCV SPRINT 55 heavily pretreated 55 GHRH 55 Rebif ® 55 Peg IFN 55 immunomodulatory 55 null responders 55 GeoVax vaccine 55 HZT 55 angiogenesis inhibitor 55 investigational monoclonal antibody 55 PEGylated 55 HBeAg positive patients 55 phase IIb study 55 voreloxin 55 EndoTAG TM -1 55 NN# [001] 55 generation FBPase inhibitor 55 CUDC 55 bexarotene 55 Civacir 55 HCV NS5B polymerase 55 ISTODAX 55 interferon 55 chronic HCV 55 COPEGUS 55 Maribavir 55 neuraminidase inhibitor 55 targeting CD# 55 CIMZIA ™ 55 ILLUMINATE 55 rindopepimut 55 Quinamed 55 alpha interferon 55 VFEND 55 ADAGIO study 55 ProSavin 55 nelfinavir 55 Pegasys R 55 Homspera 55 pegylated alpha interferon 55 PENNVAX B 55 tigecycline 55 hematological tumors 55 ulimorelin 55 Vicriviroc 55 mAb 55 Factor VIIa 55 VZV 55 Aliskiren 55 pharmacodynamic effects 55 Gammagard 55 HCV NS3 protease 55 immunomodulating 55 virologic response 55 subcutaneous formulation 55 pharmacokinetic properties 55 BAL# [002] 55 Glufosfamide 55 Phase 2b trial 55 rPA 55 safety tolerability pharmacokinetics 55 Talabostat 55 Aganocide 55 ALK inhibitor 55 VEGF inhibitor 55 darunavir ritonavir 55 adalimumab 55 telcagepant 55 deforolimus 55 ZADAXIN ® 55 CG# [003] 55 Zoraxel 55 tolvaptan 55 mg TID 55 Phase IIb clinical 55 clinical pharmacology studies 55 trastuzumab DM1 T DM1 55 protein kinase inhibitor 55 superficial bladder cancer 54 humanized antibodies 54 Empatic 54 tyrosine kinase inhibitor 54 DAVANAT 54 RiVax 54 tasocitinib 54 IIa trial 54 OMP #M# 54 mertansine 54 hA# 54 RSD# oral 54 Sphingomab 54 lopinavir 54 ataluren 54 hepatitis C HCV 54 ONCONASE R 54 octreotide acetate 54 Phase 2b clinical 54 pegylated interferon peg IFN 54 EGFR TKIs 54 micafungin 54 tolerability profiles 54 FOSRENOL ® 54 dose proportional pharmacokinetics 54 ELACYT 54 KRN# 54 Phase IIa 54 ACZ# 54 GRN# 54 Anthim 54 quinolone 54 amprenavir 54 DsiRNA 54 prucalopride 54 PEG IFN 54 NeuroVax TM 54 bortezomib Velcade 54 tenofovir emtricitabine 54 alicaforsen enema 54 HCV nucleoside 54 SVR# 54 alpha 2a 54 monotherapy 54 maturation inhibitors 54 NNRTI resistance 54 davunetide intranasal AL 54 Boceprevir 54 LE DT 54 Bortezomib 54 milatuzumab 54 Phase 2a clinical 54 SPC# [001] 54 MAGE A3 ASCI 54 undetectable HCV RNA 54 TELCYTA 54 peptide antigens 54 pralatrexate 54 L BLP# 54 cobiprostone 54 omecamtiv mecarbil 54 investigational pan BCR 54 pharmacokinetic interactions 54 BNC# 54 TRO# 54 Crizotinib 54 Nanobody ® 54 Veronate 54 Trofex 54 transcriptase inhibitors NNRTIs 54 Hemopurifier 54 virologic suppression 54 trastuzumab emtansine T DM1 54 Relovair 54 interferon therapy 54 BZL# 54 NRTIs 54 bactericidal activity 54 Ramoplanin 54 #D#C# 54 undetectable viral loads 54 Solulin 54 AZILECT R 54 seroconversion 54 LT NS# 54 peg interferon 54 AzaSite Plus 54 Panzem 54 metreleptin 54 DEB# 54 MLN# 54 fosamprenavir 54 INVEGA ® 54 telaprevir dosing 54 nucleoside analog 54 BHT DNA 54 GPNMB 54 liprotamase 54 Lixivaptan 54 PROMACTA 54 CD# antibody [001] 54 Imprime PGG 54 interferon ribavirin 54 vandetanib 54 albinterferon alfa 2b 54 pre exposure prophylaxis 54 renal toxicity 54 generation antisense 54 castrate resistant prostate cancer 54 epothilones 54 BCX# 54 XOMA 3AB 54 Carfilzomib 54 Sprycel dasatinib 54 PROCHYMAL 54 Targretin 54 AZT zidovudine Retrovir 54 BRIM3 54 aflibercept VEGF Trap 54 intranasal delivery 54 VLPs 54 Onalta 54 peginterferon alfa 2b 54 investigational therapies 54 immunogenicity 54 placebo controlled Phase 54 Vaxfectin 54 safinamide 54 Sapacitabine 54 BARACLUDE R 54 sJIA 54 preclinical efficacy 54 BioVant 54 sitaxsentan 54 orally dosed 54 TYGACIL 54 ketolide antibiotic 54 AVE# 54 crizotinib 54 non nucleoside reverse 54 pertuzumab 54 novel peptide 54 tiapamil 54 arbaclofen 54 PEG interferon 54 Phase 1a 54 LB# [003] 54 midstage clinical 54 siRNA therapeutic 54 PMX # 54 Tarvacin Anti Viral 54 pafuramidine 54 investigational compound 54 JAK3 54 TKI therapy 54 PNT# 54 virological response 54 Azixa 54 tgAAC# 54 metastatic renal cell carcinoma 54 nucleoside analogs 54 LTBI 54 C1 INH 54 noninferiority 54 MEK inhibitor 54 NEUMUNE 54 pegylated interferon alfa 54 Phase IIb trial 54 romidepsin 54 humanized monoclonal antibody 54 sodium glucose cotransporter 54 motesanib 54 RNAi therapeutic 54 AVP #D# 54 IND submission 54 eliglustat tartrate 54 rhIL 7 54 imatinib 54 CDK inhibitor 54 HBeAg positive 54 alfa 2a 54 hepatitis C virus HCV 54 TransVax ™ 54 CDP# 54 Phase Ib II 54 pramlintide 54 adecatumumab 54 Rasagiline 54 selective agonist 54 JAK2 inhibitor 54 disease modifying 54 MPS IVA 54 alkylating agent 54 darunavir 54 2 methoxyestradiol 54 vivo efficacy 54 QVA# 54 mcg doses 54 TYZEKA 54 oral rivaroxaban 54 HEPLISAV 54 INCB# [003] 54 AACR NCI EORTC 54 THR beta agonist 54 HuLuc# 54 Vitaxin 54 interferon beta 54 regorafenib 54 efavirenz Sustiva 54 TOCOSOL Paclitaxel 54 antiviral compounds 54 Hepsera 54 Ceflatonin 54 IND enabling 54 cetuximab Erbitux R 54 systemic RNAi therapeutic 54 carcinoid syndrome 54 SinuNase TM 54 GATTEX 54 pemetrexed Alimta 54 daclizumab 54 Perifosine 54 optimal dosing 54 NOX E# 54 amikacin 54 reslizumab 54 interferon gamma 1b 54 Zybrestat 54 MT#/MEDI-# 54 EGFr 54 alemtuzumab Campath 54 Virologic 54 Virulizin ® 54 NAbs 54 methylnaltrexone 54 CCR5 tropic 54 darapladib 54 refractory CLL 54 plus Copegus R 54 gefitinib 54 TTR gene 54 NOXAFIL 54 ibandronate 54 talactoferrin 54 Cinquil 54 lenalidomide Revlimid R 54 telaprevir dosed 54 EGFR inhibitors 54 canakinumab 54 imetelstat 54 menadione 54 Anidulafungin 54 abacavir lamivudine 54 phase Ib 54 A3 adenosine receptor 54 volociximab 54 anti VEGF 54 DAVANAT ® 54 PRX# 54 Nuvion 54 tipifarnib 54 pyrazinamide 54 Huntexil 53 abiraterone acetate 53 indibulin 53 GelVac TM 53 gemifloxacin 53 ruboxistaurin 53 CCR5 tropic HIV 53 DDP# 53 PBT2 53 ALISTA 53 busulfan 53 XL# [003] 53 VIR# 53 ZFP Therapeutic 53 Anticalin R 53 forodesine hydrochloride 53 BENLYSTA TM 53 iroxanadine 53 histone deacetylase HDAC inhibitor 53 peginterferon alfa 53 DAS# [001] 53 huN# DM1 53 TMC# r 53 hGH CTP 53 Octreotide 53 nab paclitaxel 53 inhaled formulation 53 PrEP 53 omacetaxine mepesuccinate 53 REYATAZ r 53 ATHX 53 Vaprisol 53 rilonacept 53 HCV polymerase 53 pharmacokinetic studies 53 entinostat 53 Leukine 53 cediranib 53 voriconazole 53 immunostimulatory 53 Stimuvax R